Wakamoto Pharmaceutical Co., Ltd. (JP:4512)

:4512

4512

Wakamoto Pharmaceutical Co., Ltd.

RESEARCH TOOLSreports

Want to see JP:4512 full AI Analyst Report?

Wakamoto Pharmaceutical Co., Ltd. (4512) Price & Analysis

0 Followers

4512 Stock Chart & Stats

¥286.00

-¥4.00(-1.79%)

At close: Jan 08 4:00 PM EST

¥286.00

-¥4.00(-1.79%)

Day’s Range― - ―

52-Week Range¥240.00 - ¥380.00

Previous CloseN/A

Volume100.70K

Average Volume (3M)65.94K

Market Cap

¥8.92B

Enterprise Value¥7.24B

Total Cash (Recent Filing)¥3.56B

Total Debt (Recent Filing)¥100.00M

Price to Earnings (P/E)39.3

Beta0.44

Next Earnings

Jul 31, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield1.06%

Share Statistics

EPS (TTM)-5.12

Shares Outstanding34,838,326

10 Day Avg. Volume55,010

30 Day Avg. Volume65,936

Financial Highlights & Ratios

PEG Ratio0.21

Price to Book (P/B)1.01

Price to Sales (P/S)1.23

P/FCF Ratio-11.59

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Strong Balance SheetA conservatively financed balance sheet with minimal debt gives the company durable financial flexibility. Over the next 2–6 months this supports funding for working capital, R&D or product rollouts without refinancing risk, and provides a buffer while cash flows recover.

Revenue Growth & Profitability RecoverySustained ~27% top-line growth and a return to positive EBIT/net income indicate structural demand for core products and improving execution. If maintained, this trend can expand scale economics, support margin recovery, and improve medium-term earnings resilience.

Stable High Gross MarginsConsistently high gross margins reflect durable pricing power or efficient production economics in its digestive/health product lines. This structural margin advantage provides room to absorb SG&A or input-cost increases and supports long-term profitability improvement potential.

Bears Say

Persistent Negative Cash FlowThree years of negative operating and free cash flow materially weaken cash conversion and increase reliance on reserves despite low leverage. Over months this constrains reinvestment capacity, limits margin recovery options, and raises funding risk for growth or dividends.

Thin Net Margins And Earnings VolatilityVery slim net margins (~2%) leave little cushion against cost shocks or demand softness. Historical swings between losses and positive years signal execution and demand risk; persistent volatility undermines sustainable cash generation and planning for medium-term investments.

Low Returns On EquityA large equity base combined with low ROE indicates the firm struggles to convert capital into profitable returns. Over time this signals suboptimal capital allocation, potential pressure to pursue higher-risk initiatives, and limits attractiveness to long-term income-focused investors.

4512 FAQ

What was Wakamoto Pharmaceutical Co., Ltd.’s price range in the past 12 months?

Wakamoto Pharmaceutical Co., Ltd. lowest stock price was ¥240.00 and its highest was ¥380.00 in the past 12 months.

What is Wakamoto Pharmaceutical Co., Ltd.’s market cap?

Wakamoto Pharmaceutical Co., Ltd.’s market cap is ¥8.92B.

When is Wakamoto Pharmaceutical Co., Ltd.’s upcoming earnings report date?

Wakamoto Pharmaceutical Co., Ltd.’s upcoming earnings report date is Jul 31, 2026 which is in 38 days.

How were Wakamoto Pharmaceutical Co., Ltd.’s earnings last quarter?

Wakamoto Pharmaceutical Co., Ltd. released its earnings results on May 15, 2026. The company reported ¥0.35 earnings per share for the quarter, beating the consensus estimate of N/A by ¥0.35.

Is Wakamoto Pharmaceutical Co., Ltd. overvalued?

According to Wall Street analysts Wakamoto Pharmaceutical Co., Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Wakamoto Pharmaceutical Co., Ltd. pay dividends?

Wakamoto Pharmaceutical Co., Ltd. pays a Annually dividend of ¥3.473 which represents an annual dividend yield of 1.06%. See more information on Wakamoto Pharmaceutical Co., Ltd. dividends here

What is Wakamoto Pharmaceutical Co., Ltd.’s EPS estimate?

Wakamoto Pharmaceutical Co., Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Wakamoto Pharmaceutical Co., Ltd. have?

Wakamoto Pharmaceutical Co., Ltd. has 34,838,326 shares outstanding.

What happened to Wakamoto Pharmaceutical Co., Ltd.’s price movement after its last earnings report?

Wakamoto Pharmaceutical Co., Ltd. reported an EPS of ¥0.35 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.734%.

Which hedge fund is a major shareholder of Wakamoto Pharmaceutical Co., Ltd.?

Currently, no hedge funds are holding shares in JP:4512

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Wakamoto Pharmaceutical Co., Ltd.

Headquartered in Tokyo, Japan, Wakamoto Pharmaceutical Co., Ltd. specializes in the production and distribution of both prescription and over-the-counter pharmaceuticals across the country. Their diverse offerings include Strong Wakamoto, a widely recognized gastrointestinal aid formulated to enhance digestion, regulate intestinal health, and supplement nutrition. Additionally, the company provides AVANTBISE oral tablets, a dietary supplement designed to rebalance the oral microbiome, as well as various medicated toothpastes. Founded in 1929, the enterprise was initially known as Society for Nutrition and Raising Children Co., Ltd. before formally changing its name to Wakamoto Pharmaceutical Co., Ltd. in July 1943.